← Back to headlines
Stock Market: The risk of the... weekend that investors fear
CervoMed (CRVO)'s fourth-quarter results highlight significant advancements in its Neflamapimod program, targeting Dementia Lewy Bodies (DLB).
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Amazon's First Customer Receipt Goes Viral, Bezos and Musk React
just now
Four Arrested for Selling P102 Million in Counterfeit Anti-Cancer Medicine in Makati
just now
Philippines receives diesel shipment from Malaysia
just now
DPWH Vows Completion of Stalled Laguna Medical Center Building by 2027
just now